Unlocking New Hope for Spinal Cord Injuries

A revolutionary study from the University of Toronto's Temerty Faculty of Medicine reveals that riluzole, a drug widely used in treating amyotrophic lateral sclerosis (ALS), might also be a lifesaver for those suffering from spinal cord injuries. Researchers propose that this medication could significantly enhance recovery if administered within 12 hours post-injury.

Promising Results and Groundbreaking Methods

Published in the esteemed journal eBioMedicine, the study led by senior scientist Michael Fehlings emphasizes the vehicle of progress. "This is a very valid and safe treatment option for clinicians and patients to consider," he stated, underscoring the robust data backing their findings.

The research stems from a PhD thesis by co-author Karlo Pedro, who has transitioned to assistant professor of surgery at the same institution. A significant highlight of this study is the use of the innovative Global Statistical Test (GST)—a groundbreaking statistical analysis tool that provides a comprehensive view of how therapies impact patients over multiple stages of recovery, rather than relying on a single measure.”},{